![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
LBP-EC01 is a Locus crPhage® therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome.
Lead Product(s): LBP-EC01,Trimethoprim,Sulfamethoxazole
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Under terms of this partnership, Somerset Pharma will supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19, to Premier.
Lead Product(s): Sulfamethoxazole,Trimethoprim
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020